BUSINESS
    Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
    By Hayate Horiguchi September 15, 2026
    Moderna is looking to oncology as a key pillar of future growth, with its recent PIII win for a personalized mRNA cancer vaccine providing important validation for a field where the company already has nine…

    LATEST

    MSD Files Oral PCSK9 Inhibitor Enlicitide in Japan
    September 15, 2026
    MSD said on September 14 that it has filed its once-daily oral PCSK9 inhibitor enlicitide in Japan for hypercholesterolemia and familial hypercholesterolemia, seeking to bring a tablet option to a class currently available only as…
    Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
    September 15, 2026
    Takeda Pharmaceutical said on September 14 that the US FDA has accepted its new drug application for zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, under priority review for the treatment of adults with…
    CMIC Names CFO Yoshida as New President
    September 15, 2026
    Japanese contract research organization CMIC said on September 14 that Takanobu Yoshida, currently director, executive vice president and CFO, will become representative director and president effective October 1.Yoshida will take over the reins from current…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
    By Ken Yoshino

    Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA